Business UpdateJun 23, 2026, 04:06 PM
Artiva Biotherapeutics to Present at H.C. Wainwright Virtual Conference
AI Summary
Artiva Biotherapeutics announced that its management will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 3:30 pm EDT. An audio webcast and archived recording will be accessible via the Investors section of Artiva's website for 90 days. The company is a clinical-stage biotechnology firm developing cell therapies for autoimmune diseases, with its lead program AlloNK (AB-101) slated for a Phase 3 trial in refractory rheumatoid arthritis in 2026.
Key Highlights
- Artiva management to participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference.
- Fireside chat scheduled for Tuesday, June 30, 2026, at 3:30 pm EDT.
- Audio webcast and archived recording will be available on Artiva's Investors section.
- Archived webcast will remain available for replay for 90 days.
- Artiva is a clinical-stage biotechnology company focused on autoimmune diseases.
- Lead program AlloNK (AB-101) is an allogeneic NK cell therapy.
- Company plans to initiate a Phase 3 registrational trial for AlloNK in refractory RA in 2026.
Price Impact
More from ARTV